Chlorpheniramine is named as an intervention in 2 current clinical trials in our China and Egypt registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (1). The most-studied condition is Allergic Transfusion Reaction.
Of the three regulators tracked here, the first to approve Chlorpheniramine was the US, on 13 Jul 1949.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Antihistamine for Prevention of HTR After Blood Primed CPB
NCT07536152 · ClinicalTrials.gov ↗ · Blood Transfusion Associated Adverse Reactions
|
Phase 4 | Recruiting | Kasr El Aini Hospital | Egypt |
|
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
NCT04688736 · ClinicalTrials.gov ↗ · Allergic Transfusion Reaction
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Chlorpheniramine on the HPRA medicines list.
No entry for Chlorpheniramine in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Kasr El Aini Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Egypt registers name Chlorpheniramine as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Institute of Hematology & Blood Diseases Hospital, China (1) and Kasr El Aini Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Chlorpheniramine, for example Piriton Allergy 4mg Tablets (Haleon Ireland Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Chlorpheniramine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Chlorpheniramine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Chlorpheniramine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Chlorpheniramine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.